Ilex Medical (ILX) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Ilex Medical stock ILS 77.11, price ILS 47.04, upside +63.9%, quality 64 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 43.03 ILS – 148.22 ILS · fair‑value band 54.91 ILS – 104.35 ILS · the 47.04 ILS price screens below the 77.11 ILS fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Ilex Medical in your weekly email
Every Wednesday you see whether Ilex Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Ilex Medical Ltd engages in the import, marketing, distribution and sale of medical laboratory equipment and various diagnostic products, diagnostic systems, and kits and consumables in Israel, the United States, and internationally.
Show moreShow less
The company also provides laboratory services, as well as is involved in the development, production, marketing and sale of software systems for information management in medical laboratories.
Its products are used for performing tests in hospital medical laboratories, blood banks and health insurance funds, as well as for providing application and technical services to users. Ilex Medical Ltd was incorporated in 1990 and is based in Petah Tikva, Israel.
Stock analysis
Ilex Medical (ILX) currently trades at 47.04 ILS, while our model-based Fair Value estimate is 77.11 ILS, implying the stock looks roughly 39% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 102.89 ILS per share, and 17 of the 26 models we run sit above the 47.04 ILS price.
Bear case: the Dividend Discount group reads lowest at 11.20 ILS, and 9 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 54.91 ILS (bear) to 104.35 ILS (bull), the price of 47.04 ILS sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 64/100 (solid quality), in the Healthcare sector.
Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Ilex Medical reported revenue of 931M ILS in FY2025 versus 1.1B ILS in FY2021, a compound −3.2%/yr. Reported net income was 55.6M ILS in FY2025, compounding −27.2%/yr from FY2021.
Key figures
Market cap 526M ILS Micro · P/E ratio 13.5 · P/S ratio 0.59 · EPS (TTM) 3.48 ILS · Dividend yield 4.2% · Net margin 4.4% · Return on equity 5.9% · Return on assets (EBIT) 13.3% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 30% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 33% fair-value upside, at 64%, ILX screens cheaper than that median.
Fair Value models
Bear54.91 ILSFair Value 77.11 ILSBull104.35 ILS
Price 47.04 ILS · Upside +63.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (1.28 ILS per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
+1.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.3%
Start year 2020 (pandemic). Over 10 years: +6.5% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−11.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−15.2%
Dividend (yield on the price)4.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−15.2% vs 6.0%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 6%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−1.4%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Israel: IMF forecast 2.1% a year to 2030, 1.7% from 2016 to 2025) that is about −3.4% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 77 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score64 · Top 25%
Fair Value upside+63.9% · Above median
Profitability
Return on equity (12 months)5.9% · Below median
Return on assets5.6% · Top 25%
Net margin (12 months)4.4% · Top 25%
Operating margin (12 months)2.5% · Below median
Growth and dividend
Revenue growth (quarter YoY)−9.5% · Bottom 25%
Dividend yield (12 months)4.2% · Above median
Valuation Multiplesvs Medical Distribution median · lower = cheaper
P/E (12 months)13.5× · Cheaper than median
P/B0.77× · Cheaper than median
P/S (12 months)0.59× · Pricier than median
Price / free cash flow (fiscal year)12.3× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Ilex Medical Fair Value". https://www.fairvalue-calculator.com/stock/ILX
Frequently asked questions
Is Ilex Medical (ILX) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 77.11 ILS versus a price of 47.04 ILS, about +64% upside (undervalued).
What is the fair value of ILX?
Our model-based fair value for Ilex Medical is 77.11 ILS (as of Nov 8, 2026), built from audited fundamentals. The current price: 47.04 ILS.
What is the quality score of ILX?
Ilex Medical has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ilex Medical (ILX)?
Our model-based price target is the fair value of 77.11 ILS (as of Nov 8, 2026) from 26 valuation models. Cautious scenario 54.91 ILS, optimistic scenario 104.35 ILS. It is a calculation from audited fundamentals, not an analyst target.
What is the Ilex Medical stock forecast for 2026?
Our models put fair value at 77.11 ILS, about +64% upside versus a price of 47.04 ILS (undervalued). Cautious scenario 54.91 ILS, optimistic scenario 104.35 ILS. The calculation is refreshed regularly with new filings.
What is the revenue of Ilex Medical (ILX)?
Ilex Medical reported trailing-twelve-month revenue of about 885M ILS (latest available figure, as of Nov 8, 2026).
Does Ilex Medical pay a dividend?
Ilex Medical currently shows a dividend yield of 4.22% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Ilex Medical (ILX) and when is the ex-dividend date?
Ilex Medical pays a dividend of 1.99 ILS per share a year, a dividend yield of 4.2%. The last ex-dividend date was Apr 10, 2026. A dividend has been paid every year since 2021. The payout ratio is 57.1% of earnings. Free cash flow covers the dividend 1.93 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Ilex Medical (ILX)?
For today's price to be fair in a discounted-cash-flow model, Ilex Medical would have to grow free cash flow by -1.4 % per year for five years (discount rate 14.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -0.3 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of ILX use?
Our models discount Ilex Medical at 14.6 %: a base by market capitalisation (micro), country premium for Israel. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Ilex Medical that is -1.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (14.6 %) and the same formula as our fair value.
How much growth has Ilex Medical (ILX) delivered so far?
Over the past 5 years revenue at Ilex Medical grew -0.3 % a year. The price currently implies free-cash-flow growth of -1.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Ilex Medical (ILX) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Ilex Medical (-1.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Ilex Medical (ILX)?
The free-cash-flow yield on the price is 8.13 %: that much free cash flow Ilex Medical produces per unit of market value. When it exceeds the discount rate of our models (14.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Ilex Medical (ILX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ilex Medical it is 77.11 ILS per share (as of Nov 8, 2026), against a price of 47.04 ILS. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Ilex Medical stock overvalued or undervalued in 2026?
As of Nov 8, 2026, ILX trades below its calculated fair value: price 47.04 ILS, fair value 77.11 ILS, a gap of about +64% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ILX?
No. The price is what the market pays today (47.04 ILS); the fair value is what the company's own numbers justify (77.11 ILS). For Ilex Medical the two are 30.07 ILS per share apart. That gap is exactly why we show both numbers side by side.
How much is Ilex Medical worth?
The market values Ilex Medical at about 526M ILS (market capitalisation, as of Nov 8, 2026). Per share that is 47.04 ILS; our models calculate a fair value of 77.11 ILS per share.
What do the bullish and bearish scenarios say about ILX?
Our models span a range for Ilex Medical: cautious scenario 54.91 ILS, base 77.11 ILS, optimistic 104.35 ILS per share (as of Nov 8, 2026, price 47.04 ILS). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ILX?
Ilex Medical trades at a price-to-earnings ratio of 13.5 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 77.11 ILS is built from several models across several years. Other multiples: P/B 0.8, P/S 0.6, EV/EBITDA 4.7.
How solid is the balance sheet of Ilex Medical (ILX)?
Balance-sheet figures for Ilex Medical (as of Nov 8, 2026): return on equity 5.9%. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is ILX from its 52-week high?
Ilex Medical trades at 47.04 ILS, about 30% below its 52-week high of 67.56 ILS and 9% above the low of 43.03 ILS (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 77.11 ILS is for.
Which stocks are comparable to Ilex Medical?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ilex Medical stock attractive at the current price?
The data as of Nov 8, 2026: price 47.04 ILS, calculated fair value 77.11 ILS (+64%), Quality Score 64/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ILX calculated?
We run Ilex Medical through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 77.11 ILS builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Ilex Medical currently trades 39% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ilex Medical (ILX)?
The closing price on Nov 6, 2026 was 47.04 ILS. Our model-based fair value is 77.11 ILS, about +64% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ilex Medical right now?
The price is below even our cautious bear case (54.91 ILS). The market is more pessimistic than our downside scenario. Solid quality (64/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (54.91 ILS to 104.35 ILS) leaves room in how you read the outcome.
Where does the earnings growth of Ilex Medical (ILX) come from?
Earnings per share at Ilex Medical grew +5.5 % a year from 2014 to 2025. Broken into its drivers: revenue per share +6.2 %, EBIT margin −0.9 %, tax rate +0.1 %, residual (interest, one-offs) +0.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Ilex Medical
How large is the market capitalisation of Ilex Medical (ILX)?
The market capitalisation of Ilex Medical is 526M ILS. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ilex Medical (ILX)?
The price-to-sales ratio of Ilex Medical is 0.59 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ilex Medical (ILX)?
Earnings per share at Ilex Medical are 3.48 ILS (price ÷ EPS = P/E 13.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Ilex Medical (ILX)?
The dividend yield of Ilex Medical is 4.2% (payout 57.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Ilex Medical (ILX)?
The net margin of Ilex Medical is 4.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ilex Medical (ILX)?
The return on equity (ROE) of Ilex Medical is 5.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ilex Medical (ILX)?
On an EBIT basis the return on assets of Ilex Medical is 13.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ilex Medical (ILX)?
The operating margin of Ilex Medical is 2.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ilex Medical (ILX)?
Revenue at Ilex Medical is growing −9.5% versus a year earlier (3y avg +2.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Ilex Medical (ILX)?
Earnings per share at Ilex Medical are growing −73.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Ilex Medical (ILX) hold?
Ilex Medical holds more cash than debt, 129M ILS net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Ilex Medical in the live analysis
One click puts Ilex Medical on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026